# Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial

> **NCT05053802** · PHASE2 · RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 146 (estimated)

## Conditions studied

- Multiple Primary Lung Cancer

## Interventions

- **COMBINATION_PRODUCT:** Microwave ablation plus Camrelizumab
- **DEVICE:** Microwave ablation

## Key facts

- **NCT ID:** NCT05053802
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-21
- **Primary completion:** 2025-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05053802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05053802, "Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05053802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*